SignPath Pharma, Inc.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas (NCT05768919) | SignPath Pharma, Inc. | 2023-03-03 |
| A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer (NCT02138955) | SignPath Pharma, Inc. | 2014-03-01 |
| Evaluation of Liposomal Curcumin in Healthy Volunteers (NCT01403545) | SignPath Pharma, Inc. | 2011-08-01 |
Track SignPath Pharma, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.